Envestnet Asset Management
BSTC

Envestnet Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Envestnet Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,107
Closed -$48K – 3187
2015
Q4 		$48K Sell
1,107
-38
-3% -$1.9K ﹤0.01% 2696
2015
Q3 		$50K Buy
+1,145
New +$61.8K ﹤0.01% 2661

Other funds holding BSTC

ACA
Abdiel Capital Advisors New York $52M AUM 13.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Envestnet Asset Management's BSTC Position: Q1 2016 in Review

Envestnet Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2016, closing a stake of 1,107 shares — an estimated $48K sold.

Envestnet Asset Management first reported a position in BSTC in Q3 2015 and held it in 2 quarters. The position peaked at $50K in Q3 2015. 91 funds tracked by Wall St. Rank hold BSTC as of Q1 2016.

  • Envestnet Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q1 2016 after selling out during the quarter.
  • Envestnet Asset Management sold 1,107 BioSpecifics Technologies Corp. shares in Q1 2016, an estimated $48K.
  • Envestnet Asset Management first reported a position in BioSpecifics Technologies Corp. in Q3 2015 and held it in 2 quarters.
  • Envestnet Asset Management's BioSpecifics Technologies Corp. position peaked at $50K in Q3 2015.
  • 91 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2016.

Based on Envestnet Asset Management's 13F filing for Q1 2016, filed 16 May 2016.